Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
Division of Infectious Diseases, Department of Internal Medicine, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.
J Microbiol Immunol Infect. 2018 Jun;51(3):287-301. doi: 10.1016/j.jmii.2017.07.005. Epub 2017 Jul 25.
The Infectious Diseases Society of Taiwan (IDST), the Hematology Society of Taiwan, the Taiwan Society of Blood and Marrow Transplantation, Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education, and CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines cooperatively published this guideline for the use of antifungal agents in hematological patients with invasive fungal diseases (IFDs) in Taiwan. The guideline is the first one endorsed by IDST focusing on selection of antifungal strategies, including prophylaxis, empirical (or symptom-driven) and pre-emptive (or diagnostic-driven) strategy. We suggest a risk-adapted dynamic strategy and provide an algorithm to facilitate decision making in population level as well as for individual patient. Risk assessment and management accordingly is explicitly emphasized. In addition, we highlight the importance of diagnosis in each antifungal strategy among five elements of the antimicrobial stewardship (diagnosis, drug, dose, de-escalation and duration). The rationale, purpose, and key recommendations for the choice of antifungal strategy are summarized, with concise review of international guidelines or recommendation, key original articles and local epidemiology reports. We point out the interaction and influence between elements of recommendations and limitation of and gap between evidences and daily practice. The guideline balances the quality of evidence and feasibility of recommendation in clinical practice. Finally, this version introduces the concept of health economics and provides data translated from local disease burdens. All these contents hopefully facilitate transparency and accountability in medical decision-making, improvements in clinical care and health outcomes, and appropriateness of medical resource allocation.
台湾感染症医学会、台湾血液暨骨髓移植学会、台湾血液与骨髓移植移植学会、成大纪念医院医学研究基金会、谢政达教授感染症研究与教育基金会、李永进小儿感染暨疫苗研究发展基金会共同发布此台湾血液恶性肿瘤患者侵袭性真菌疾病抗真菌药物使用指引。此指引为台湾感染症医学会针对抗真菌药物策略选择之指引,涵盖预防、经验性(或症状驱动)及抢先性(或诊断驱动)策略。我们建议采用风险适应的动态策略,并提供一个演算法,以协助在群体层面及个别病患做出决策。我们也明确强调风险评估与管理的重要性。此外,我们也在抗微生物药物管理的五个要素(诊断、药物、剂量、降阶与疗程)中强调各抗真菌策略下诊断的重要性。我们总结了选择抗真菌策略的理由、目的和关键建议,并简要回顾了国际指引或建议、关键原始文献和本地流行病学报告。我们指出了建议要素之间的相互作用和影响,以及证据和日常实践之间的局限性和差距。本指引平衡了临床实践中证据质量和推荐可行性。最后,此版本介绍了卫生经济学的概念,并提供了从本地疾病负担翻译的数据。所有这些内容都希望能提高医疗决策的透明度和问责制,改善临床护理和健康结果,并适当分配医疗资源。